Evaluating the impact of daratumumab for the treatment of multiple myeloma according to cytogenetic risk

Bookmark and Share
Published: 10 Jul 2020
Views: 257
Rating:
Save
Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA

Dr Luciano Costa speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He outlines the premise and methodology of this study, which conducted a meta-analysis to evaluate the impact of daratumuab for the treatment of multiple myeloma (MM), according to cytogenetic risk.

Dr Costa explains the results from this analysis, which screened a total of 3070 studies, including 6 phase III trials.

He concludes that the addition of daratumumab to the backbone of regimens improved progression-free survival in newly-diagnosed MM (NDMM) and relapsed/refractory MM (RRMM) patients with high-risk cytogenetics.